Cargando…

20(S)-Protopanaxadiol Inhibits Titanium Particle-Induced Inflammatory Osteolysis and RANKL-Mediated Osteoclastogenesis via MAPK and NF-κB Signaling Pathways

Osteolysis is a principal reason for arthroplasty failure like aseptic loosening induced by Titanium (Ti) particle. It is a challenge for orthopedic surgeons. Recent researches show that 20(S)-protopanaxadiol can inhibit inflammatory cytokine release in vitro. This study aims to assess the effect of...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Chenhao, Shan, Haojie, Wu, Tianyi, Liu, Wei, Lin, Yiwei, Xia, Wenyang, Wang, Feng, Zhou, Zubin, Yu, Xiaowei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345703/
https://www.ncbi.nlm.nih.gov/pubmed/30713497
http://dx.doi.org/10.3389/fphar.2018.01538
_version_ 1783389604775198720
author Pan, Chenhao
Shan, Haojie
Wu, Tianyi
Liu, Wei
Lin, Yiwei
Xia, Wenyang
Wang, Feng
Zhou, Zubin
Yu, Xiaowei
author_facet Pan, Chenhao
Shan, Haojie
Wu, Tianyi
Liu, Wei
Lin, Yiwei
Xia, Wenyang
Wang, Feng
Zhou, Zubin
Yu, Xiaowei
author_sort Pan, Chenhao
collection PubMed
description Osteolysis is a principal reason for arthroplasty failure like aseptic loosening induced by Titanium (Ti) particle. It is a challenge for orthopedic surgeons. Recent researches show that 20(S)-protopanaxadiol can inhibit inflammatory cytokine release in vitro. This study aims to assess the effect of 20(S)-protopanaxadiol on Ti particle-induced osteolysis and RANKL-mediated osteoclastogenesis. Micro-CT and histological analysis in vivo indicated the inhibitory effects of 20(S)-protopanaxadiol on osteoclastogenesis and the excretion of inflammatory cytokines. Next, we demonstrated that 20(S)-protopanaxadiol inhibited osteoclast differentiation, bone resorption area, and F-actin ring formation in a dose-dependent manner. Moreover, mechanistic studies suggested that the suppression of MAPK and NF-κB signaling pathways were found to mediate the inhibitory effects of 20(S)-protopanaxadiol. In conclusion, 20(S)-protopanaxadiol may suppress osteoclastogenesis in a dose- dependent manner and it could be a potential treatment of Ti particle-induced osteolysis.
format Online
Article
Text
id pubmed-6345703
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-63457032019-02-01 20(S)-Protopanaxadiol Inhibits Titanium Particle-Induced Inflammatory Osteolysis and RANKL-Mediated Osteoclastogenesis via MAPK and NF-κB Signaling Pathways Pan, Chenhao Shan, Haojie Wu, Tianyi Liu, Wei Lin, Yiwei Xia, Wenyang Wang, Feng Zhou, Zubin Yu, Xiaowei Front Pharmacol Pharmacology Osteolysis is a principal reason for arthroplasty failure like aseptic loosening induced by Titanium (Ti) particle. It is a challenge for orthopedic surgeons. Recent researches show that 20(S)-protopanaxadiol can inhibit inflammatory cytokine release in vitro. This study aims to assess the effect of 20(S)-protopanaxadiol on Ti particle-induced osteolysis and RANKL-mediated osteoclastogenesis. Micro-CT and histological analysis in vivo indicated the inhibitory effects of 20(S)-protopanaxadiol on osteoclastogenesis and the excretion of inflammatory cytokines. Next, we demonstrated that 20(S)-protopanaxadiol inhibited osteoclast differentiation, bone resorption area, and F-actin ring formation in a dose-dependent manner. Moreover, mechanistic studies suggested that the suppression of MAPK and NF-κB signaling pathways were found to mediate the inhibitory effects of 20(S)-protopanaxadiol. In conclusion, 20(S)-protopanaxadiol may suppress osteoclastogenesis in a dose- dependent manner and it could be a potential treatment of Ti particle-induced osteolysis. Frontiers Media S.A. 2019-01-18 /pmc/articles/PMC6345703/ /pubmed/30713497 http://dx.doi.org/10.3389/fphar.2018.01538 Text en Copyright © 2019 Pan, Shan, Wu, Liu, Lin, Xia, Wang, Zhou and Yu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Pan, Chenhao
Shan, Haojie
Wu, Tianyi
Liu, Wei
Lin, Yiwei
Xia, Wenyang
Wang, Feng
Zhou, Zubin
Yu, Xiaowei
20(S)-Protopanaxadiol Inhibits Titanium Particle-Induced Inflammatory Osteolysis and RANKL-Mediated Osteoclastogenesis via MAPK and NF-κB Signaling Pathways
title 20(S)-Protopanaxadiol Inhibits Titanium Particle-Induced Inflammatory Osteolysis and RANKL-Mediated Osteoclastogenesis via MAPK and NF-κB Signaling Pathways
title_full 20(S)-Protopanaxadiol Inhibits Titanium Particle-Induced Inflammatory Osteolysis and RANKL-Mediated Osteoclastogenesis via MAPK and NF-κB Signaling Pathways
title_fullStr 20(S)-Protopanaxadiol Inhibits Titanium Particle-Induced Inflammatory Osteolysis and RANKL-Mediated Osteoclastogenesis via MAPK and NF-κB Signaling Pathways
title_full_unstemmed 20(S)-Protopanaxadiol Inhibits Titanium Particle-Induced Inflammatory Osteolysis and RANKL-Mediated Osteoclastogenesis via MAPK and NF-κB Signaling Pathways
title_short 20(S)-Protopanaxadiol Inhibits Titanium Particle-Induced Inflammatory Osteolysis and RANKL-Mediated Osteoclastogenesis via MAPK and NF-κB Signaling Pathways
title_sort 20(s)-protopanaxadiol inhibits titanium particle-induced inflammatory osteolysis and rankl-mediated osteoclastogenesis via mapk and nf-κb signaling pathways
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345703/
https://www.ncbi.nlm.nih.gov/pubmed/30713497
http://dx.doi.org/10.3389/fphar.2018.01538
work_keys_str_mv AT panchenhao 20sprotopanaxadiolinhibitstitaniumparticleinducedinflammatoryosteolysisandranklmediatedosteoclastogenesisviamapkandnfkbsignalingpathways
AT shanhaojie 20sprotopanaxadiolinhibitstitaniumparticleinducedinflammatoryosteolysisandranklmediatedosteoclastogenesisviamapkandnfkbsignalingpathways
AT wutianyi 20sprotopanaxadiolinhibitstitaniumparticleinducedinflammatoryosteolysisandranklmediatedosteoclastogenesisviamapkandnfkbsignalingpathways
AT liuwei 20sprotopanaxadiolinhibitstitaniumparticleinducedinflammatoryosteolysisandranklmediatedosteoclastogenesisviamapkandnfkbsignalingpathways
AT linyiwei 20sprotopanaxadiolinhibitstitaniumparticleinducedinflammatoryosteolysisandranklmediatedosteoclastogenesisviamapkandnfkbsignalingpathways
AT xiawenyang 20sprotopanaxadiolinhibitstitaniumparticleinducedinflammatoryosteolysisandranklmediatedosteoclastogenesisviamapkandnfkbsignalingpathways
AT wangfeng 20sprotopanaxadiolinhibitstitaniumparticleinducedinflammatoryosteolysisandranklmediatedosteoclastogenesisviamapkandnfkbsignalingpathways
AT zhouzubin 20sprotopanaxadiolinhibitstitaniumparticleinducedinflammatoryosteolysisandranklmediatedosteoclastogenesisviamapkandnfkbsignalingpathways
AT yuxiaowei 20sprotopanaxadiolinhibitstitaniumparticleinducedinflammatoryosteolysisandranklmediatedosteoclastogenesisviamapkandnfkbsignalingpathways